| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/05/2004 | CN1148367C Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same |
| 05/05/2004 | CN1148350C Novel VLA-4 inhibitor: oMePUPA-V |
| 05/05/2004 | CN1148346C Hydrazine derivs. |
| 05/05/2004 | CN1148227C Therapeutic compound and its application |
| 05/05/2004 | CN1148201C Medicine for auxiliary feedback treatment of tumour of digestive system |
| 05/05/2004 | CN1148200C Chinese herbal medicine for treating cancers |
| 05/05/2004 | CN1148185C Inhibitor for generation of 3-deoxyglucurone |
| 05/05/2004 | CN1148184C Composite medicine for optical dynamic treatment of tumor |
| 05/05/2004 | CN1148183C Indoly-3-glyoxylic acid derivatives with antitumoral activity |
| 05/05/2004 | CN1148181C Use of flavnolignanes for the prepn. of medicaments with antiproliferative activity in uterus, ovary and breast |
| 05/05/2004 | CN1148180C Compounds for treatment of estrogen-dependent illnesses and methods for making and using same |
| 05/05/2004 | CN1148179C 20-Hete antagonists and agonists |
| 05/04/2004 | US6730695 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for V1b and V1a arginine-vasopressin receptors |
| 05/04/2004 | US6730664 The side-effects of chemotherapy are suppressed or reduced |
| 05/04/2004 | US6730658 Stimulation of lymphatic growth with an FLT4 ligand |
| 05/04/2004 | US6730511 Vectors that repress heterologous promoter activity |
| 05/04/2004 | US6730489 Antibodies to truncated VEGF-D and uses thereof |
| 05/04/2004 | US6730486 Human βTrCP protein |
| 05/04/2004 | US6730324 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 05/04/2004 | US6730301 Mediating chemotaxis and activation of monocytes; athero-sclerosis; monocyte chemoattractant protein-1 (mcp-1) |
| 05/04/2004 | US6730300 Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
| 05/04/2004 | CA2240296C Endothelial cell proliferation inhibitor and method of use |
| 04/29/2004 | WO2004035776A1 Apparatus for introducing biological material, method of introducing biological material and magnetic support for introducing biological material |
| 04/29/2004 | WO2004035629A2 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 04/29/2004 | WO2004035616A2 Adenovirus expressing genes in reverse order and use thereof |
| 04/29/2004 | WO2004035615A2 Factor involved in metastasis and uses thereof |
| 04/29/2004 | WO2004035613A2 4-methylhexanoic kahalaide f compound |
| 04/29/2004 | WO2004035611A2 Peptides binding the phosphatase 2a protein and polynucleotides encoding same |
| 04/29/2004 | WO2004035601A1 Ship 1 modulators |
| 04/29/2004 | WO2004035590A2 Meso-substituted porphyrins |
| 04/29/2004 | WO2004035582A1 Pyrrolo (3,4-c) carbazole and pyrido (2,3-b) pyrrolo (3,4-e) indole derivatives, preparation method and pharmaceutical compositions containing same |
| 04/29/2004 | WO2004035581A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 04/29/2004 | WO2004035580A1 Reactivation of wild type p53 in human tumour cells by a low molecular weight compound |
| 04/29/2004 | WO2004035572A1 N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n’-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
| 04/29/2004 | WO2004035568A1 Benzofuran derivatives, formulations and uses thereof |
| 04/29/2004 | WO2004035548A1 Novel compounds |
| 04/29/2004 | WO2004035536A2 Azo compounds for type i phototherapy |
| 04/29/2004 | WO2004035525A1 Inhibitors of histone deacetylase |
| 04/29/2004 | WO2004035089A1 Remedy for hormone-dependent cancer |
| 04/29/2004 | WO2004035088A1 Therapeutics/diagnostics for brain tumor |
| 04/29/2004 | WO2004035085A1 Gene vaccine |
| 04/29/2004 | WO2004035065A1 Hypoglycemic substances containing zinc |
| 04/29/2004 | WO2004035055A1 Use of dopamine receptor agonists for the treatment of cutaneous tumors, warts, and scars |
| 04/29/2004 | WO2004035050A1 Use of epothilone derivatives for the treatment of hyperparathyroidism |
| 04/29/2004 | WO2004035045A1 Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer |
| 04/29/2004 | WO2004035043A1 Clofarabine and platinum chemotherapy combination |
| 04/29/2004 | WO2004035034A2 Clofarabine and taxane chemotherapy combination |
| 04/29/2004 | WO2004035033A2 Clofarabine and camptothecin chemotherapy combination |
| 04/29/2004 | WO2004035032A2 Pharmaceutical formulations of camptothecine derivatives |
| 04/29/2004 | WO2004035021A2 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/29/2004 | WO2004034970A2 Macrocyclic lactams |
| 04/29/2004 | WO2004034965A2 Method for treating cancer |
| 04/29/2004 | WO2004022040A3 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist |
| 04/29/2004 | WO2004018472A3 Pyrimido compounds having antiproliferative activity |
| 04/29/2004 | WO2004017940A3 Pharmaceutically active lipid based formulation of sn38 |
| 04/29/2004 | WO2004014906A3 Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents |
| 04/29/2004 | WO2004011402A3 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 04/29/2004 | WO2004007770A3 Method for diagnosis of intestinal-type gastric tumors |
| 04/29/2004 | WO2004003185A3 Plant deoxyribonucleoside kinase enzymes and their use |
| 04/29/2004 | WO2004000230A3 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders |
| 04/29/2004 | WO2003101996A8 Esters in position 20 of camptothecins |
| 04/29/2004 | WO2003099823A3 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 04/29/2004 | WO2003097649A3 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
| 04/29/2004 | WO2003093242A3 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/29/2004 | WO2003086282A3 Nitric oxide donors, compositions and methods of use |
| 04/29/2004 | WO2003075840A3 Human antibodies specific to kdr and uses thereof |
| 04/29/2004 | WO2003074524A3 Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs |
| 04/29/2004 | WO2003057134A3 Specific binding agents of human angiopoietin-2 |
| 04/29/2004 | WO2003053473A3 Ph-sensitive polymeric conjugates of an anthracycline drug |
| 04/29/2004 | WO2003025171A9 Modulation of retinoic acid receptor gene expression and therapeutic uses thereof |
| 04/29/2004 | WO2003020949A3 Targeted nucleic acid constructs and uses related thereto |
| 04/29/2004 | WO2003013537A9 Irinotecan for treatment of cancer |
| 04/29/2004 | WO2003013536A9 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 04/29/2004 | WO2003013535A9 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 04/29/2004 | WO2003013534A9 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 04/29/2004 | WO2003013533A9 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 04/29/2004 | WO2003009812A3 Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| 04/29/2004 | WO2003003004A3 Method for identifying compounds the specifically deplete mast cells |
| 04/29/2004 | WO2002102787A3 Novel sulfonic acid derivatives |
| 04/29/2004 | WO2002079169A8 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 04/29/2004 | WO2002072630A3 Nucleic acid-associated proteins |
| 04/29/2004 | WO2002070748A3 Response of dendritic cells to a diverse set of pathogens |
| 04/29/2004 | WO2002070669A3 Secreted proteins |
| 04/29/2004 | WO2002064134A8 Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies |
| 04/29/2004 | WO2002043771A9 Conjugates of glycosylated/galactosylated peptide |
| 04/29/2004 | WO2002043651A8 Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
| 04/29/2004 | WO2001095899A8 Pharmaceutical compositions comprising cannabidiol derivatives |
| 04/29/2004 | WO2001082953A8 Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| 04/29/2004 | US20040082802 26,27-Homologated-20-EPI-2-alkyl-19-nor-vitamin D compounds |
| 04/29/2004 | US20040082791 Crystals of benzimidazole compounds |
| 04/29/2004 | US20040082790 Piperidine amides as modulators of chemokine receptor activity |
| 04/29/2004 | US20040082789 Thieno[2,3-c]iosquinolines for use as inhibitors of parp |
| 04/29/2004 | US20040082787 Chemical compounds |
| 04/29/2004 | US20040082781 Bicyclic nitrogenous fused-ring compound |
| 04/29/2004 | US20040082764 Complex of antibodic and antibiotic with carrier |
| 04/29/2004 | US20040082645 Drug for detaching tumor |
| 04/29/2004 | US20040082642 Novel estrogen receptor ligands and method III |
| 04/29/2004 | US20040082639 Antitumor agents; restenosis; antiarthritic agents; antidiabetic agents |
| 04/29/2004 | US20040082638 Compounds, compositions and methods |
| 04/29/2004 | US20040082637 Heterocyclic topoisomerase poisons |